Variety of qualified clients: CDEC reviewed the uncertainty in the volume of patients with reasonably severe to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some individuals who are classified as acquiring delicate or